Loading...
XNAS
QURE
Market cap792mUSD
May 30, Last price  
14.47USD
1D
-2.89%
1Q
10.04%
Jan 2017
158.39%
IPO
7.90%
Name

Uniqure NV

Chart & Performance

D1W1MN
P/E
—
P/S
29.21
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.99%
Rev. gr., 5y
30.08%
Revenues
27m
+71.17%
004,063,9065,697,01810,304,37525,098,00013,107,00011,284,0007,281,00037,514,000524,002,000106,483,00015,843,00027,119,000
Net income
-240m
L-22.34%
00000-73,374,000-80,389,000-83,304,000-128,011,000-125,024,000329,589,000-126,789,000-308,478,000-239,556,000
CFO
-183m
L+25.22%
000018,776,375-72,189,000-64,270,000-76,037,000-98,684,000-134,828,000287,959,000-145,060,000-145,929,000-182,728,000
Earnings
Jul 30, 2025

Profile

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
URL
http://www.uniqure.com/
IPO date
Feb 05, 2014
Employees
501
Domiciled in
NL
Incorporated in
NL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
27,119
71.17%
15,843
-85.12%
106,483
-79.68%
Cost of revenue
197,706
228,492
200,934
Unusual Expense (Income)
NOPBT
(170,587)
(212,649)
(94,451)
NOPBT Margin
Operating Taxes
2,429
1,921
(1,470)
Tax Rate
NOPAT
(173,016)
(214,570)
(92,981)
Net income
(239,556)
-22.34%
(308,478)
143.30%
(126,789)
-138.47%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,123
308
1,445
BB yield
-0.25%
-0.10%
-0.14%
Debt
Debt current
3,601
16,688
8,382
Long-term debt
77,197
166,725
174,611
Deferred revenue
Other long-term liabilities
453,732
412,736
10,269
Net debt
(314,187)
(434,479)
(209,834)
Cash flow
Cash from operating activities
(182,728)
(145,929)
(145,060)
CAPEX
(3,368)
(7,154)
(17,688)
Cash from investing activities
162,968
(205,686)
(182,734)
Cash from financing activities
(59,486)
362,721
1,445
FCF
(131,750)
(162,072)
(110,744)
Balance
Cash
367,521
617,892
352,843
Long term investments
27,464
39,984
Excess cash
393,629
617,100
387,503
Stockholders' equity
(1,179,820)
(941,079)
(637,384)
Invested Capital
1,692,861
1,708,238
1,266,554
ROIC
ROCE
EV
Common stock shares outstanding
48,649
47,671
46,735
Price
17.66
160.86%
6.77
-70.14%
22.67
9.31%
Market cap
859,144
166.21%
322,733
-69.54%
1,059,483
9.06%
EV
544,957
(111,746)
849,649
EBITDA
(157,946)
(200,749)
(85,914)
EV/EBITDA
0.56
Interest
63,741
41,557
11,704
Interest/NOPBT